SEC Comment Letter 0000000000-24-006387 to Hewlett Packard Enterprise Co (HPE)
Hewlett Packard Enterprise Co
Date: June 4, 2024 · CIK: 0001645590 · Accession: 0000000000-24-006387
AI Filing Summary & Sentiment
File numbers found in text: 001-37483
Show Raw Text
United States securities and exchange commission logo
June 4, 2024
Marie Myers
Executive Vice President and Chief Financial Officer
Hewlett Packard Enterprise Co
1701 East Mossy Oaks Road
Spring, Texas 77389
Re:Hewlett Packard Enterprise Co
Current Report on Form 8-K
Filed January 19, 2024
File No. 001-37483
Dear Marie Myers:
We have reviewed your filing and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Current Report on Form 8-K filed January 19, 2024
Item 1.05 Material Cybersecurity Incidents
1.We note the statement that you experienced a cybersecurity incident, and your
investigation of the incident and its scope remains ongoing. Please advise us as to why
you determined to file under Item 1.05 of Form 8-K given the statement that the incident
has not had a material impact on your operations, and you have not determined the
incident is reasonably likely to materially impact your financial condition or results of
operations.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameMarie Myers
Comapany NameHewlett Packard Enterprise Co
June 4, 2024 Page 2
FirstName LastName
Marie Myers
Hewlett Packard Enterprise Co
June 4, 2024
Page 2
Please contact Irene Paik at 202-551-6553 or James Lopez at 202-551-3536 with any
other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences